

# PRODUCT INFORMATION




## TAS 205

Item No. 33261

**CAS Registry No.:** 1584160-52-0  
**Formal Name:** 4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-N-[4-[4-(4-morpholinylcarbonyl)-1-piperidinyl]phenyl]-1-piperazinecarboxamide, monohydrate

**MF:** C<sub>27</sub>H<sub>36</sub>N<sub>6</sub>O<sub>4</sub> • H<sub>2</sub>O  
**FW:** 526.6  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 266 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

TAS 205 is supplied as a crystalline solid. A stock solution may be made by dissolving the TAS 205 in the solvent of choice, which should be purged with an inert gas. TAS 205 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of TAS 205 in these solvents is approximately 30 mg/ml.

TAS 205 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, TAS 205 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. TAS 205 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

TAS 205 is an inhibitor of hematopoietic prostaglandin D synthase (H-PGDS; IC<sub>50</sub> = 55.8 nM).<sup>1</sup> It is selective for H-PGDS over lipocalin-type PGDS (L-PGDS) at 100 μM, as well as over enzyme and receptor panels at 10 μM. TAS 205 inhibits production of prostaglandin D<sub>2</sub> (PGD<sub>2</sub>; Item No. 12010) induced by A23187 (Item No. 11016) in KU812 human and RBL-2H3 rat basophils with IC<sub>50</sub> values of 78.3 and 181.3 nM, respectively. It inhibits ovalbumin-induced nasal lavage fluid eosinophil infiltration and late-phase nasal obstruction in an ovalbumin-sensitized guinea pig model of allergic rhinitis when administered at a dose of 30 mg/kg.

### Reference

1. Aoyagi, H., Kajiwara, D., Tsunekuni, K., *et al.* Potential synergistic effects of novel hematopoietic prostaglandin D synthase inhibitor TAS-205 and different types of anti-allergic medicine on nasal obstruction in a Guinea pig model of experimental allergic rhinitis. *Eur. J. Pharmacol.* **875**, 173030 (2020).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/10/2021

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)